Trial Profile

A study to evaluate the effects of dolutegravir on body composition and glico-lipidic metabolism in HIV-infected youths

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abacavir/dolutegravir/lamivudine (Primary)
Indications HIV infections
Focus Pharmacodynamics

Most Recent Events

16 Apr 2021 Results evaluating body composition and glycolipidic metabolism in adolescents living with HIV starting a DTG-based regimen, published in the Pediatric Infectious Disease Journal
03 Apr 2020 New trial record
11 Mar 2020 Results presented at the 27th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com